Literature DB >> 12408865

The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility.

Yichin Liu1, Lara Fallon, Hilal A Lashuel, Zhihua Liu, Peter T Lansbury.   

Abstract

The assumption that each enzyme expresses a single enzymatic activity in vivo is challenged by the linkage of the neuronal enzyme ubiquitin C-terminal hydrolase-L1 (UCH-L1) to Parkinson's disease (PD). UCH-L1, especially those variants linked to higher susceptibility to PD, causes the accumulation of alpha-synuclein in cultured cells, an effect that cannot be explained by its recognized hydrolase activity. UCH-L1 is shown here to exhibit a second, dimerization-dependent, ubiquityl ligase activity. A polymorphic variant of UCH-L1 that is associated with decreased PD risk (S18Y) has reduced ligase activity but comparable hydrolase activity as the wild-type enzyme. Thus, the ligase activity as well as the hydrolase activity of UCH-L1 may play a role in proteasomal protein degradation, a critical process for neuronal health.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408865     DOI: 10.1016/s0092-8674(02)01012-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  232 in total

1.  Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy.

Authors:  Catherine Meyer-Schwesinger; Tobias N Meyer; Henning Sievert; Elion Hoxha; Marlies Sachs; Eva-Maria Klupp; Silvia Münster; Stefan Balabanov; Lucie Carrier; Udo Helmchen; Friedrich Thaiss; Rolf A K Stahl
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 3.  Roles for the ubiquitin-proteasome pathway in protein quality control and signaling in the retina: implications in the pathogenesis of age-related macular degeneration.

Authors:  Fu Shang; Allen Taylor
Journal:  Mol Aspects Med       Date:  2012-04-10

4.  Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1.

Authors:  Leonardus M I Koharudin; Hao Liu; Roberto Di Maio; Ravindra B Kodali; Steven H Graham; Angela M Gronenborn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 5.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

6.  UCH-L1 inhibition involved in CREB dephosphorylation in hippocampal slices.

Authors:  Min Xie; Shao-Hui Wang; Zhi-Min Lu; Ying Pan; Qi-Cai Chen; Xiao-Mei Liao
Journal:  J Mol Neurosci       Date:  2013-12-10       Impact factor: 3.444

7.  Rare Disease Mechanisms Identified by Genealogical Proteomics of Copper Homeostasis Mutant Pedigrees.

Authors:  Stephanie A Zlatic; Alysia Vrailas-Mortimer; Avanti Gokhale; Lucas J Carey; Elizabeth Scott; Reid Burch; Morgan M McCall; Samantha Rudin-Rush; John Bowen Davis; Cortnie Hartwig; Erica Werner; Lian Li; Michael Petris; Victor Faundez
Journal:  Cell Syst       Date:  2018-01-31       Impact factor: 10.304

8.  Ubiquitin C-terminal hydrolase L1 interacts with choline transporter in cholinergic cells.

Authors:  Sigurd Hartnett; Fan Zhang; Allison Abitz; Yifan Li
Journal:  Neurosci Lett       Date:  2014-02-11       Impact factor: 3.046

Review 9.  Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?

Authors:  Subhankar Paul; Sailendra Mahanta
Journal:  Mol Cell Biochem       Date:  2013-10-05       Impact factor: 3.396

10.  Loss of polyubiquitin gene Ubb leads to metabolic and sleep abnormalities in mice.

Authors:  K-Y Ryu; N Fujiki; M Kazantzis; J C Garza; D M Bouley; A Stahl; X-Y Lu; S Nishino; R R Kopito
Journal:  Neuropathol Appl Neurobiol       Date:  2009-12-08       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.